JP Morgan Chase
APVO icon

JP Morgan Chase’s Aptevo Therapeutics APVO Stock Holding History

JP Morgan Chase’s Portfolio APVO Stock Details APVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13
Closed -$19.5K – 7309
2024
Q4 		$19.5K Buy
+13
New +$37.4K ﹤0.01% 6252
2024
Q3 		– Hold
0
– – – 7308
2024
Q2 		– Hold
0
– – – 7192
2024
Q1 		– Hold
0
– – – 6809
2023
Q4 		– Hold
0
– – – 6979
2023
Q3 		– Hold
0
– – – 6694
2022
Q2 		– Hold
0
– -$1K – 6440
2022
Q1 		– Hold
0
– – – 6455
2020
Q3 		– Hold
0
– – – 5464
2020
Q2 		– Hold
0
– – – 5349
2020
Q1 		– Hold
0
– – – 5275
2019
Q4 		– Hold
0
– – – 5595
2019
Q3 		– Hold
0
– – – 5701
2019
Q2 		– Hold
0
– – – 5702
2019
Q1 		– Hold
0
– – – 5684
2018
Q4 		– Hold
0
– – – 5612
2018
Q3 		– Hold
0
– – – 4399
2018
Q2 		– Hold
0
– – – 3623
2018
Q1 		– Hold
0
– – – 3780
2017
Q4 		– Hold
0
– – – 4349
2017
Q3 		– Hold
0
– -$20K – 4957
2017
Q2 		– Hold
0
– – – 4538

Other funds holding APVO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

JP Morgan Chase's APVO Position: Q1 2025 in Review

JP Morgan Chase sold out of Aptevo Therapeutics (APVO) in Q1 2025, closing a stake of 13 shares — an estimated $19.5K sold.

JP Morgan Chase first reported a position in APVO in Q4 2024 and held it in 1 quarter. The position peaked at $19.5K in Q4 2024. 5 funds tracked by Wall St. Rank hold APVO as of Q1 2025.

  • JP Morgan Chase reported no remaining Aptevo Therapeutics position as of Q1 2025 after selling out during the quarter.
  • JP Morgan Chase sold 13 Aptevo Therapeutics shares in Q1 2025, an estimated $19.5K.
  • JP Morgan Chase first reported a position in Aptevo Therapeutics in Q4 2024 and held it in 1 quarter.
  • JP Morgan Chase's Aptevo Therapeutics position peaked at $19.5K in Q4 2024.
  • 5 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.